BELVIN MARCIA 4
4 · CytomX Therapeutics, Inc. · Filed Feb 4, 2026
Research Summary
AI-generated summary of this filing
CytomX (CTMX) SVP Marcia Belvin Receives 310,000-Share Award
What Happened
Marcia Belvin, SVP and Chief Scientific Officer at CytomX Therapeutics (CTMX), received equity awards on February 2, 2026: 60,000 restricted stock units (RSUs) and 250,000 derivative securities (reported as an award/derivative). Both grants show an acquisition price of $0.00 (typical for compensation awards), for a total of 310,000 shares subject to future vesting rather than an open-market purchase or sale.
Key Details
- Transaction date: February 2, 2026; Form 4 filed February 4, 2026 (within the two-business-day Form 4 window).
- Grants reported: 60,000 RSUs (Footnote F1) and 250,000 derivative awards (listed as “Derivative”) — acquisition price $0.00 for each grant.
- Footnote F1: The 60,000 RSUs convert 1:1 to common shares when vested; 1/3 of those RSUs vest annually on March 15, starting March 15, 2027, subject to continued service.
- Footnote F3: The 250,000 derivative award vests 1/48th monthly beginning Feb 2, 2026 (Vesting Commencement Date), fully vesting after four years, subject to continued service.
- Footnote F2: Filing notes “Includes 218,958 RSUs” (this relates to reported holdings in the filing). The filing does not list a complete post-transaction total of common shares beneficially owned beyond the footnoted RSU amount.
- No sale or open-market purchase was reported — these are compensation grants.
Context
- These awards are compensation grants, not purchases; they carry vesting conditions and do not represent immediately tradable shares until vested (and, for options/derivatives, exercised if applicable).
- For retail investors, grants signal continued compensation alignment with management but are routine and subject to service/vesting requirements; they do not by themselves indicate a buy or sell decision by the insider.
Insider Transaction Report
Form 4
BELVIN MARCIA
SVP, Chief Scientific Officer
Transactions
- Award
Common Stock
[F1][F2]2026-02-02+60,000→ 332,252 total - Award
Stock Option (Right to Buy)
[F3]2026-02-02+250,000→ 250,000 totalExercise: $6.09Exp: 2036-02-01→ Common Stock (250,000 underlying)
Footnotes (3)
- [F1]Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 1/3rd of the RSUs vest annually on March 15 of each year, with the first 1/3rd vesting on March 15, 2027, subject to the Reporting Person continuing as a service provider through each such date.
- [F2]Includes 218,958 RSUs.
- [F3]1/48th of the shares subject to the option vest on each monthly anniversary measured from February 2, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.
Signature
/s/ Christopher Ogden, as Attorney-in-Fact for Marcia Belvin|2026-02-04